Resources

Learn more about the progress on our groundbreaking therapeutic option for improved tendon health outcomes.

Are you a provider or patient?

Interested in participating in or learning more about clinical trials for TenoMiR®?

Sign up here.

Tell us about yourself

Provider, Patient, or Investor

Name

First Name

Last Name

Email

  
Data &
Publications

Multiple published studies validate our approach

15 July 2017

MicroRNA29a Treatment Improves Early Tendon Injury

  
Ashlee E. Watts1,4, Neal L. Millar2,4, Josh Platt1, Susan M. Kitson2, Moeed Akbar2,Raquel Rech1, Jay Griffin1, Roy Pool,1, Tom Hughes3, Iain B. McInnes2, and Derek S. Gilchrist2

10 April 2015

MicroRNA29a regulates IL-33-mediated tissue remodelling in tendon disease

  
Neal L. Millar1, Derek S. Gilchrist1, Moeed Akbar1, James H. Reilly1, Shauna C. Kerr1, Abigail L. Campbell1, George A.C. Murrell2, Foo Y. Liew1,3, Mariola Kurowska-Stolarska1 & Iain B. McInnes1

Resources

Are you a provider or patient?

Interested in participating in or learning more about clinical trials for TenoMiR®?

Sign up here.

Thank you for your Interest in our clinical research. Please add our email info@causewaytx.com to your list of approved email addresses to avoid being caught by your spam filter.

Data & Publications

Multiple published studies validate our approach

15 July 2017

MicroRNA29a Treatment Improves Early Tendon Injury

Ashlee E. Watts^1,4, Neal L. Millar^2,4, Josh Platt¹, Susan M. Kitson², Moeed Akbar²,Raquel Rech¹, Jay Griffin¹, Roy Pool,¹, Tom Hughes³, Iain B. McInnes², and Derek S. Gilchrist²

10 April 2015

MicroRNA29a regulates IL-33-mediated tissue remodelling in tendon disease

Neal L. Millar¹, Derek S. Gilchrist¹, Moeed Akbar¹, James H. Reilly¹, Shauna C. Kerr¹, Abigail L. Campbell¹, George A.C. Murrell², Foo Y. Liew^1,3, Mariola Kurowska-Stolarska¹ & Iain B. McInnes¹

Thank you for your Interest in our clinical research.

Please add our email info@causewaytx.com to your list of approved email addresses to avoid being caught by your spam filter.

Resources

Are you a provider or patient?

Interested in participating in or learning more about clinical trials for TenoMiR®? Sign up here.

Thank you for your Interest in our clinical research. Please add our email info@causewaytx.com to your list of approved email addresses to avoid being caught by your spam filter.

Data & Publications

Multiple published studies validate our approach

15 July 2017

MicroRNA29a Treatment Improves Early Tendon Injury

Ashlee E. Watts1,4, Neal L. Millar2,4, Josh Platt1, Susan M. Kitson2, Moeed Akbar2,Raquel Rech1, Jay Griffin1, Roy Pool,1, Tom Hughes3, Iain B. McInnes2, and Derek S. Gilchrist2

10 April 2015

MicroRNA29a regulates IL-33-mediated tissue remodelling in tendon disease

Neal L. Millar1, Derek S. Gilchrist1, Moeed Akbar1, James H. Reilly1, Shauna C. Kerr1, Abigail L. Campbell1, George A.C. Murrell2, Foo Y. Liew1,3, Mariola Kurowska-Stolarska1 & Iain B. McInnes1

Thank you for your Interest in our clinical research. Please add our email info@causewaytx.com to your list of approved email addresses to avoid being caught by your spam filter.

Interested in participating in or learning more about clinical trials for TenoMiR®?

Sign up here.

Ashlee E. Watts^1,4, Neal L. Millar^2,4, Josh Platt¹, Susan M. Kitson², Moeed Akbar²,Raquel Rech¹, Jay Griffin¹, Roy Pool,¹, Tom Hughes³, Iain B. McInnes², and Derek S. Gilchrist²

Neal L. Millar¹, Derek S. Gilchrist¹, Moeed Akbar¹, James H. Reilly¹, Shauna C. Kerr¹, Abigail L. Campbell¹, George A.C. Murrell², Foo Y. Liew^1,3, Mariola Kurowska-Stolarska¹ & Iain B. McInnes¹

Thank you for your Interest in our clinical research.

Please add our email info@causewaytx.com to your list of approved email addresses to avoid being caught by your spam filter.